Comparative Pharmacology
Head-to-head clinical analysis: PRAMIPEXOLE DIHYDROCHLORIDE versus REQUIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRAMIPEXOLE DIHYDROCHLORIDE versus REQUIP.
PRAMIPEXOLE DIHYDROCHLORIDE vs REQUIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Dopamine receptor agonist; exhibits high affinity for D2 and D3 receptors, and moderate affinity for D1 and D4 receptors.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
Immediate-release: Initial 0.25 mg orally three times daily; titrate weekly by 0.25 mg per dose to a total daily dose of 3 mg; max 24 mg/day. Extended-release: Initial 2 mg orally once daily; titrate by 2 mg/day at weekly intervals; max 24 mg/day.
None Documented
None Documented
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Terminal elimination half-life: approximately 5-6 hours in young healthy adults, extending to 7-9 hours in elderly patients. Clinically, dosing is typically three times daily due to this short half-life.
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Primarily renal: approximately 90% of the dose is excreted in urine, with about 60% as unchanged drug and 30% as metabolites. Fecal excretion accounts for about 10%.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist